OpGen Announces the Cancellation of Adjourned Portion of Annual Meeting

ROCKVILLE, Md., Aug. 04, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or the “Company”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, today announced that it has determined to withdraw from stockholder consideration Proposal 2 set forth in its Definitive Proxy Statement filed with the Securities and Exchange Commission on April 26, 2021, relating to an increase in the number of shares of capital stock authorized for issuance under the Company’s Amended and Restated Certificate of Incorporation. In light of the withdrawal of such proposal, the Company has determined to cancel the reconvening of the adjourned portion of its Annual Meeting of Stockholders for the consideration of Proposal 2, which was previously adjourned solely with respect to Proposal 2 to 10:00 a.m. Eastern Time on August 5, 2021. All other proposals in the Company’s Definitive Proxy Statement were previously submitted to a vote of stockholders at the Annual Meeting on June 9, 2021, at which all such proposals were approved. The Company plans to continue evaluating alternatives for financing the future development and growth of the Company.

See the article here:
OpGen Announces the Cancellation of Adjourned Portion of Annual Meeting